Search for content, post, videos

ISD Immunotech enters strategic research collaboration

research lab

ISD Immunotech has entered into a strategic research collaboration with Biogen.

ISD and Biogen will work together to develop ISD’s lead compound, ISD 017, which is being developed to treat severe lupus – systemic lupus erythematosus (SLE).  ISD 017 is a peptide therapeutic which is an inhibitor of the stimulator of interferon genes (STING) pathway. The STING pathway has recently been shown to play a central role and to be overactivated in severe lupus, a condition with a highly underserved patient population, according to the company’s press release.

“We are pleased that Biogen, a leader in drug development has selected ISD Immunotech as its collaboration partner. With its recent positive Phase 2 study results for CLE and SLE, Biogen’s interests and competencies complement ISD Immunotech’s areas of expertise in lupus, STING biology and peptide drug development,” says Tara Heitner, CEO of ISD Immunotech. “This collaboration underscores the quality of our therapeutic program and recognizes the importance of STING pathway overactivation in severe SLE. Together with Biogen, we aim to deliver one of the first new therapies to treat severe SLE in over 50 years.”

Photo: iStock